The morphology of the tumor and the anatomic extent of the disease are important factors influencing treatment selection and ultimately survival for patients with lung cancer. The American Joint Committee TNM system provides a method for consistent reproducible description of the primary tumor (T), the status of the regional lymph nodes (N), and the presence or absence of distant metastasis (M Advances in the diagnosis and therapy of lung cancer have related largely to application of a multimodality treatment concept and to refinements in the treatment selection process. Accurate, reproducible classification of histology and anatomic extent of disease is fundamental to the rational application of these elements of management.
stage III disease.
Improvements in the outcome for lung cancer patients depend upon the depth and scope of our scientific understandings and our ability to communicate our observations to one another. Measures of response to treatment can be translated into therapeutic practice only if uniform evaluators are used. Accordingly, a reproducible valid system for staging of lung cancer is recommended.
Advances in the diagnosis and therapy of lung cancer have related largely to application of a multimodality treatment concept and to refinements in the treatment selection process. Accurate, reproducible classification of histology and anatomic extent of disease is fundamental to the rational application of these elements of management.
By means of these classifications, we determine the nature of the tumor, describe its biologic behavior, and assess the therapeutic options. The results of different modalities of treatment can only be meaningful if they are based on a system of uniform evaluators. For many years pathologists have directed their efforts toward providing consistent criteria for histologic classification of lung cancer that mini-mized interobserver variability. Classification of disease extent using the TNM system makes possible a common language for describing the total tumor burden in a given patient at any specific point in the course of the disease. Accordingly, a clinical stage, surgical evaluative stage, a postsurgical treatment-pathologic stage, retreatment stage, and autopsy stage may all be applicable. Using this scheme and the histologic information, a quantitative estimate of a patient's prognosis can be made. Furthermore, the anatomic extent of disease expressed in terms of the primary tumor, the regional lymph nodes, and distant metastasis serves as a valuable aid in treatment planning.
The definitions for the TNM factors and stage grouping rules shown in Tables I  and 2 were developed by the Task Force on the Lung of the American Joint Committee for Cancer Staging and End Results Reporting [1] . These recommendations were based on the analysis of survival patterns in a large series of patients with primary lung cancer treated according to conventional or standard modalities.
The survival studies showed that a specific survival pattern for each major histologic grouping, regardless of any other tumor, host, or therapeutic influence, exists, and three significantly different survival patterns were evident according to measures of disease extent for patients with squamous cell, large cell, and adenocarcinoma [2] . The necessity of reporting end results by cell type was clearly shown. No parameters could be identified that affected the survival in patients with undifferentiated small cell carcinoma and it was originally thought not to be worthwhile to apply the staging system to them. Recent improvements in the treatment of patients with small cell carcinoma with multidrug chemotherapy and multimodality treatment have resulted in an increase of survival rate, especially in those with limited extent of disease, and, therefore, it is now advisable to apply the TNM classification and stage grouping to patients with this cell type. End results should be reported separately for the major histologic groupings or at least according to small cell and non-small cell subsets.
STAGE GROUPING IN CARCINOMA OF THE LUNG
The "T" component describes the primary tumor and numerical descriptors, T1, T2, and T3, reflect the survival dynamics, which are related to tumor size and location, extent of proximal margination, and complications such as atelectasis, obstructive pneumonitis, and pleural effusion. The "N" component describes the regional lymph nodes and the survival dynamics, reflected by numeric descriptors, NO, N 1, and N2, are related to the absence of or to the presence and extent of such involvement. The "M" component describes distant metastasis and survival is related to the presence or absence of such metastasis, MO or M1. The TNM subsets thus classified are combined into three stages of disease, the patients in each stage having relatively similar expectations for survival.
STAGE I DISEASE
The different common presentations of Stage I disease are shown in Fig. 1 TI NO MO DISEASE Figure 2 illustrates the typical roentgenographic appearance of T1 NO MO disease in a 60-year-old female patient who was a non-smoker. This lesion was found on routine follow-up X-ray 14 years postdefinitive treatment for squamous cell carcinoma of the cervix. The lesion was, however, considered to be a primary bronchogenic carcinoma. Sputum cytology was negative, as was the distal metastatic screen. Bronchoscopy revealed no endobronchial lesions and the findings at surgery confirmed the clinical stage assignment. Pathological report of the wedge resection of the right upper lobe of the lung was reported as bronchogenic squamous carcinoma and direct transition from bronchiolar respiratory mucosa with tumor was identified, substantiating lung origin. Hilar and mediastinal lymph node biopsies were negative. STAGE II DISEASE Stage II disease consists of just one subset, illustrated in Fig. 3 , that is, T2 lesions having involvement of the peribronchial and/or hilar nodes either through direct extension or metastasis. The disease is technically completely resectable, but survival expectations for non-small cell patients with Stage II disease vary according to histologic classification. In squamous cell carcinoma, involvement of the regional lymphatic structures does not carry as heavy a burden of mortality as in the other cell types. Involvement ofLthe hilar nodes in the presence of a tumor larger than 3 cm causes a marked drop in survival expectations in patients with adenocarcinoma. Shown in Fig. 3 T2 N I DISEASE This patient, whose X-ray is shown in Fig. 4 , is a 71-year-old male whose disease was discovered when he sought emergency medical attention for trauma to the chest from a fall. A routine chest X-ray revealed a left ninth rib fracture and a left upper lung mass. Figure 4 DISTANT METASTATIC SITES The presence of distant metastasis outside the ipsilateral hemithorax and the mediastinum, regardless of the T or N value, is indicative of Stage III disease and is classified M1. Except in anecdotal cases, this usually is synonymous with a fatal outcome.
The TNM system can be applied to most patients with lung cancer with certainty and the appropriate stage designated with consistency. One group of 15 patients was staged independently by 26 physicians and research assistants with more than 90 percent consistency in the TNM designations and stage assignment [4] .
A system of classification which takes into account all variables influencing survival would be hopelessly complex and unmanageable. be classified in any one described subset of the total population. Furthermore, it must be remembered that no two patients are completely similar nor can their characteristics be completely described. In practice, we can only group together patients who are generally alike. This is done by abstracting certain common features and disregarding or omitting other aspects that are dissimilar.
The following suggestions are made as conventions which may be followed in the interest of consistency. TO is to be used when there is no demonstrable evidence of the primary tumor in the lung but there is evidence of metastatic cancer in a lymph node or elsewhere justifying a N 1 or N2 or M1 designation, and it is concluded clinically that the primiary is in the lung. TO may also be used in the Retreatment Staging of a patient who had resection of his cancer and has proof of recurrence in the regional lymph nodes or a distant metastasis without evidence of recurrence in the lung.
SUGGESTIONS FOR APPLICATION OF THE LUNG CANCER STAGING SYSTEM
TX is used when a patient has a positive sputum for malignant cells but a negative roentgenogram of the chest and a negative bronchoscopic examination. Such a designation is usually temporary as in most cases the source of the positive sputum can be localized and an appropriate T designation can be assigned. A clinical stage assignment of TX NO MO could be made. TX may also be used in the Retreatment Staging when it is impossible to evaluate the extent of residual primary tumor after radiotherapy and the development of radiation pneumonitis and fibrosis in the field of radiotherapy.
T2 is used when there is direct extension into the visceral pleura, but T3 is used if the lesion directly invades the parietal pleura. Any ipsilateral discontinuous lesion or lesions in or on the visceral or parietal pleura should be designated T3. However, a discontinuous lesion outside the parietal pleura in the chest wall or diaphragm should be designated Ml. In contrast, a similar lesion in the mediastinum is most likely a lymph node that has been completely replaced by cancer cells and should be designated N2.
Ipsilateral multiple primary tumors of the same cell type or unknown cell type should be classified T2 unless there is other evidence of T3 disease.
Clinical classification of hilar masses may be difficult. If the hilar mass can be separated from the mediastinum, hilar tomograms or computerized axial tomography (CAT) may indicate whether the mass is the primary tumor or metastatic disease in the hilar lymph nodes and the appropriate T and N designation assigned to the patient. If the hilar mass cannot be separated from the mediastinum, especially if there is a broad base of the lesion against the mediastinum, direct extension into the mediastinum is probable and the lesion should be designated T3. Vocal cord paralysis, superior vena caval obstruction, and compression of the trachea or the esophagus are usually related to metastases to the mediastinal lymph nodes and, if not proven otherwise, should be classified N2.
The M I designation should be used only when there is reasonable proof of metastatic cancer, not when it is only possible. For example, elevated serum alkaline phosphatase without other evidence of metastatic cancer in liver or bone would not justify the designation Ml.
In all cases, the designation of the greatest extent of disease that is applicable for a given patient should be used, but only when there is reasonable evidence of that extent of disease. It is recognized that a number of other factors beyond morphology and anatomic extent of disease are important in the classification of lung cancer and these are recognized and accounted for in the AJC recommendations, as follows:
First, the host performance status, (H), which is correlated with activity of disease and prognosis, should be recorded before first treatment and at each subsequent examination of the patient. Over a decade ago, Feinstein described the importance of comorbidity as an index of tumor aggressiveness and growth rate [5] follows: HO is equivalent to normal activity; H 1 represents symptomatic and ambulatory status-patient is able to care for himself; H2 includes patients ambulatory more than 50 percent of the time, occasionally needing assistance; H3 includes those patients ambulatory 50 percent or less of the time, nursing care needed, and H4 indicates a bedridden condition-the patient may need hospitalization.
Second, when the cancer is treated by definitive surgical procedures, residual cancer, designated R, is recorded if any such disease is present. RO signifies no residual tumor, R 1, microscopic residual tumor, and R2, macroscopic residual turmor.
